Panacea Biotec Ltd., one of India’s leading biotechnology and pharmaceutical companies, has been in the spotlight for delivering extraordinary returns to its investors. Over the past year, the stock has surged nearly 190–200%, and in the past three years, it has gained over 200%, cementing its position as a true multibagger.
However, despite this remarkable long-term growth, the stock has recently faced some downward pressure, with declines seen in short-term performance.
Panacea Biotec Current Share Price & Market Snapshot
As of August 11, 2025, Panacea Biotec shares were trading in the range of ₹390–₹411. Economic Times reported a price of ₹390.15 at 3:16 PM IST, down from the previous ₹409.45. Moneycontrol, on the other hand, listed the stock at ₹411.50, compared to its previous close of ₹410.60.
The stock’s 52-week range has been wide, with a high of ₹581.90 and a low of ₹133.47, showing the dramatic price movement in recent months. According to Screener.in, Panacea Biotec’s current market price stands near ₹409, with a book value of ₹136. The company has a dividend yield of 0% and a negative return on equity (ROE) and return on capital employed (ROCE) of around –5%, reflecting recent financial challenges.
Panacea Biotec Returns Profile — A True Multibagger
Panacea Biotec’s long-term performance tells a different story from its recent declines. Over the past year, the stock has delivered returns of about +190–207%, according to multiple market sources such as Economic Times, Kotak Securities, and ICICI Direct. In the three-year period, the returns have been similarly impressive, at around +195–203%.
Here’s a breakdown of the returns as of August 11, 2025:
| Period | Return |
|---|---|
| 1 Week | –5–5.3% |
| 1 Month | –6.3–6.4% |
| 3 Months | –20–20.5% |
| 1 Year | ~190–190.5% |
| 3 Years | ~203–203.97% |
These figures highlight why investors still see Panacea Biotec as a multibagger stock despite its recent pullback. The share’s journey from its 52-week low to recent highs has rewarded long-term holders significantly.
Fundamentals & Financial Risks
While Panacea Biotec’s stock price tells an exciting growth story, the company’s fundamentals present a more cautious picture. The stock trades at a high price-to-book ratio of around 3.0 and has a very low or negative price-to-earnings (P/E) ratio due to recent losses.
Financial performance has been under pressure, with the company reporting a net loss of ₹1.99 crore in the fourth quarter of FY25, according to The Economic Times and INDmoney. Profitability metrics such as ROE and ROCE remain negative, pointing to ongoing operational and cost challenges.
Despite these issues, market sentiment has stayed positive over the long term. Analysts suggest that the optimism may be driven by expectations of future growth in the biotech sector and the company’s potential to turn around its earnings in upcoming quarters. However, with volatility in the share price and high valuations, risk remains a key factor for new investors.
Outlook & Investor Sentiment
In summary, Panacea Biotec stands as a prime example of how stock market success stories often come with underlying risks. The company’s shares have delivered ~190–200% returns over the past year and ~200%+ over three years, proving its multibagger status. At the same time, the recent decline of over 4–5% in a day and nearly 20% in the past three months shows that momentum can shift quickly.
Investors are now keenly awaiting the next quarterly results to gauge whether Panacea Biotec can reverse its profitability concerns. For long-term holders, the journey so far has been highly rewarding, but going forward, the balance between growth potential and financial health will be critical.
F.A.Q.
– Why is Panacea Biotec called a multibagger stock?
Panacea Biotec is considered a multibagger because it has delivered nearly 190–200% returns in the past year and over 200% in the past three years, significantly multiplying investors’ wealth.
– What is the 52-week high and low of Panacea Biotec?
The stock’s 52-week high is ₹581.90, and the 52-week low is ₹133.47, showing a wide trading range.
– Is Panacea Biotec profitable right now?
No, the company has reported recent net losses, including a loss of ₹1.99 crore in Q4 FY25, and currently shows negative ROE and ROCE.
– Should investors buy Panacea Biotec now?
While the stock has delivered exceptional long-term returns, recent declines, high valuations, and ongoing financial losses mean investors should be cautious and consider their risk tolerance before investing.
Also read:-